# Tafamidis

Drug · id `cardio:tafamidis` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Vyndamax; Vyndaqel

Browse, condition area: Heart failure  

## In plain language

Tafamidis is the medicine inside Vyndamax and Vyndaqel. The US label describes it as a selective stabilizer of transthyretin, the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization. The atlas holds no trial results for it.

## Technical summary

RxNorm ingredient 1545063. Two FDA applications: NDA212161 (Vyndamax, tafamidis) and NDA211996 (Vyndaqel, tafamidis meglumine, whose marketing status is discontinued in the Drugs@FDA record although the label record still names the brand). One label record, version 15, covers both brands. The mechanism comes from that label.

## Claims, with the population each applies to

## Context: Adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary), as described in the US label of Vyndaqel and Vyndamax

Recipient: Adult; Population: Adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), as the label states its indication.; Care setting: Prescription medicine taken by mouth; the label record states no care setting; Geography: United States (labeling approved by the US Food and Drug Administration); Life stage: Adults; Follow-up: Not applicable (regulatory and labeling statement)

### The openFDA records list two tafamidis applications, both with an original submission approved on 3 May 2019: NDA212161 for Vyndamax (tafamidis; class Type 2 - New Active Ingredient; applicant FOLDRX PHARMS), listed as a prescription product, and NDA211996 for Vyndaqel (tafamidis meglumine; class Type 1 - New Molecular Entity), listed as discontinued. One label record (version 15, effective 12 May 2026) still names both brands and says they are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular mortality and cardiovascular-related hospitalization.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM), as the label states its indication.; Care setting: Prescription medicine taken by mouth; the label record states no care setting; Geography: United States (labeling approved by the US Food and Drug Administration); Life stage: Adults; Follow-up: Not applicable (regulatory and labeling statement)
- Limitations: An FDA approval is a decision about a medicine, not a finding about how much it helps any person. The discontinued status of Vyndaqel is the marketing status in the openFDA application record, and the label record still lists the brand, so the two sources are given side by side without reconciling them. The two applications are for different forms of the substance (the meglumine salt and tafamidis itself). The label record is a copy and may not show later changes. openFDA says not to rely on its data for decisions about medical care. The atlas gives no dose.
- Last checked: 2026-10-30
- Sources:
  1. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Application number of Vyndamax.
  2. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Applicant.
  3. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Brand name.
  4. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].products\[0\].active\_ingredients\[0\].name. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Active ingredient.
  5. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].submissions\[1\].submission\_status\_date. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Date of the original approval, written as eight digits.
  6. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].submissions\[1\].submission\_class\_code\_description. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Class of the original submission.
  7. Supports: FDA drug application NDA212161 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA212161&limit=1>
     Locator: results\[0\].products\[0\].marketing\_status. Retrieved 2026-10-30T19:45:01Z. Source state: Current. Version fingerprint: f7d5e9261e264536e18103c451268668b072cfc86890bf257d2e1ced3f66ca39.
     How it applies: Marketing status of Vyndamax.
  8. Supports: FDA drug application NDA211996 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211996&limit=1>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:45:02Z. Source state: Current. Version fingerprint: 90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0.
     How it applies: Application number of Vyndaqel.
  9. Supports: FDA drug application NDA211996 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211996&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-10-30T19:45:02Z. Source state: Current. Version fingerprint: 90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0.
     How it applies: Brand name.
  10. Supports: FDA drug application NDA211996 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211996&limit=1>
     Locator: results\[0\].products\[0\].active\_ingredients\[0\].name. Retrieved 2026-10-30T19:45:02Z. Source state: Current. Version fingerprint: 90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0.
     How it applies: Active ingredient.
  11. Supports: FDA drug application NDA211996 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211996&limit=1>
     Locator: results\[0\].submissions\[0\].submission\_status\_date. Retrieved 2026-10-30T19:45:02Z. Source state: Current. Version fingerprint: 90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0.
     How it applies: Date of the original approval, written as eight digits.
  12. Supports: FDA drug application NDA211996 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211996&limit=1>
     Locator: results\[0\].submissions\[0\].submission\_class\_code\_description. Retrieved 2026-10-30T19:45:02Z. Source state: Current. Version fingerprint: 90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0.
     How it applies: Class of the original submission.
  13. Supports: FDA drug application NDA211996 (openFDA Drugs@FDA record) (Regulator, edition The openFDA drugsfda record returned on 2026-10-30, from a dataset last updated 2026-10-29.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA211996&limit=1>
     Locator: results\[0\].products\[0\].marketing\_status. Retrieved 2026-10-30T19:45:02Z. Source state: Current. Version fingerprint: 90b962b450f0e44797fa2289cb1a55261912ffb6c35947de3e1a7109d6907ad0.
     How it applies: Marketing status of Vyndaqel.
  14. Supports: Vyndaqel and Vyndamax drug label (openFDA record, set id 1b4121ee-a733-4456-a917-be2603477839) (Label, edition openFDA drug label record, label version 15, effective 20260512, dataset last updated 2026-10-30. One label covers both Vyndaqel and Vyndamax.) <https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1b4121ee-a733-4456-a917-be2603477839>
     Locator: results\[0\].indications\_and\_usage\[0\]. Retrieved 2026-10-30T19:48:32Z. Source state: Current. Version fingerprint: bedf5f095796dfdac9f9344d3cc362424ca403537b52a20b748c8cda7b0eb226.
     How it applies: Indication in the label record.

## Connected pages

- US label indication: cardiomyopathy of transthyretin amyloidosis in adults: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`) [a claim, not a settled fact; see claim `cardio:claim-tafamidis-label-indication` and its context]
- Tafamidis is a selective stabilizer of transthyretin (US drug label): Transthyretin stabilizers and transthyretin-directed RNA interaction medicines (`cardio:transthyretin-directed-medicines`)
- Filed under this front: Medicines (`cardio:front-medicines`)
- Related to: Acoramidis (`cardio:acoramidis`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 2 registry products
- 2 registry trials

## Provenance

Content hash: 41621e727b1a3a4da5ae713b99fa1cba48d0bbc23344dd54f70ba372f7483478
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
